Definite total radical resection in treatment of patients, suffering low-differentiated cancer of the bladder

Keywords: low-differentiated cancer of the bladder; radical total resection of the bladder; survival.


Objective. To determine the operative volume of surgical treatment in total radical resection of the bladder in autonomous regime and to estimate the survival indices in patients with low-differentiated cancer of the bladder depending on time of conduction of radical total resection of the bladder.

Materials and methods. Retrospectively 522 histories of the diseases were analyzed in the patients with diagnosis of low-differentiated cancer of the bladder, including 190, in whom radical total resection of the bladder was performed in 1998 - 2016 yrs period. The survival indices were determined. Using Kaplan-Meier method, comparative analysis of the survival indices in patients was done, to whom radical total resection or salvage resection of the bladder performed.

Results. Total radical resection of the bladder in autonomous regime was done in 24.7% patients with low-differentiated cancer of the bladder or in 67.9% patients, to whom total resection of the bladder was performed. The indices of total 3-, 5- and 10-yr survival of the patients have constituted 96, 93 and 45%, accordingly. The survival indices in the patients after organ-preserving treatment and further salvage total resection of the bladder for locally progression of cancer were better, than in the patients, to whom the treatment consisted of primary radical total resection of the bladder, but the difference have appeared statistically nonsignificant (p=0.286). Average period between conduction of organ-preserving treatment and salvage total resection of the bladder have constituted 34 mo.

Conclusion. Radical total resection of the bladder in autonomous regime constitutes the extended method of treatment of muscularly-invaded low-differentiated cancer of the bladder (performed in 24.7% of all the patients) and guarantees satisfactory late follow-up results while primary or postponed performance.

Author Biography

P. G. Yakovlev, Center of Urology and Oncourology of Clinical Hospital “Feofania”, Kyiv

Yakovlev Pavlo, MD, PhD(Med)
Head of the Center of Urology and Oncourology,
Clinical Hospital “Feofaniya”,
1 Acad. Zabolotnogo Str., Kyiv, 03143, Ukraine.
+38 (044) 299-49-10,


Kolesnik OO, editor. Cancer in Ukraine, 2017-2018: morbidity, mortality, indicators of oncology service activity. Bulletin of the National Cancer Registry of Ukraine No 21. [Internet]. Kyiv; 2020. Available from:

Witjes JA, Bruins M, Cathomas R, Compérat E, Cowan NC, Gakis G, et al., editors. Muscle-invasive and Metastatic Bladder Cancer. EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona: EAU Guidelines Office, Arnhem, The Netherlands. 2019. ISBN 978-94-92671-07-3. Available from:

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Mar;18(3):329-54. doi: 10.6004/jnccn.2020.0011. PMID: 32135513.

Li G, Niu HM, Wu HT, Lei BY, Wang XH, Guo XB, et al. Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis. Clin Invest Med. 2017 Apr 26;40(2):E81-E94. doi: 10.25011/cim.v40i2.28199. PMID: 28447581.

Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan;191(1):40-7. doi: 10.1016/j.juro.2013.07.061. Epub 2013 Jul 30. PMID: 23911605; PMCID: PMC4158919.

Goel S, Sinha RJ, Bhaskar V, Aeron R, Sharma A, Singh V. Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade. Asian J Urol. 2019 Jul;6(3):222-9. doi: 10.1016/j.ajur.2018.06.006. Epub 2018 Jun 25. PMID: 31297313; PMCID: PMC6595093.

Audenet F, Sfakianos JP, Waingankar N, Ruel NH, Galsky MD, Yuh BE, et al. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. Urol Oncol. 2019 Feb;37(2):116-22. doi: 10.1016/j.urolonc.2018.11.011. Epub 2018 Dec 1. PMID: 30509868.

Hollenbeck BK, Dunn RL, Ye Z, Hollingsworth JM, Skolarus TA, Kim SP, et al. Delays in diagnosis and bladder cancer mortality. Cancer. 2010 Nov 15;116(22):5235-42. doi: 10.1002/cncr.25310. PMID: 20665490.

Guancial EA, Kilari D, Xiao GQ, Abu-Farsakh SH, Baran A, Messing EM, et al. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. PLoS One. 2016 May 17;11(5):e0155503. doi: 10.1371/journal.pone.0155503. PMID: 27187160; PMCID: PMC4871463.

Krabbe LM, Westerman ME, Margulis V, Raj GV, Sagalowsky AI, Courtney K, et al. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. Can J Urol. 2015 Aug;22(4):7865-75. PMID: 26267024.

Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012 May;61(5):1039-47. doi: 10.1016/j.eururo.2012.02.028. Epub 2012 Feb 22. PMID: 22381169.

Zhong J, Switchenko J, Jegadeesh NK, Cassidy RJ, Gillespie TW, Master V, et al. Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. Am J Clin Oncol. 2019 Jan;42(1):36-41. doi: 10.1097/COC.0000000000000471. PMID: 29912804; PMCID: PMC6295350.

Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2014 Feb;65(2):350-7. doi: 10.1016/j.eururo.2013.06.049. Epub 2013 Jul 3. PMID: 23849998.

Chu AT, Holt SK, Wright JL, Ramos JD, Grivas P, Yu EY, Gore JL. Delays in radical cystectomy for muscle-invasive bladder cancer. Cancer. 2019 Jun 15;125(12):2011-7. doi: 10.1002/cncr.32048. Epub 2019 Mar 6. PMID: 30840335.

McLaughlin S, Shephard J, Wallen E, Maygarden S, Carson CC, Pruthi RS. Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. Int Braz J Urol. 2007 Jan-Feb;33(1):25-31; discussion 31-2. doi: 10.1590/s1677-55382007000100005. PMID: 17335595.

Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007 Jan;51(1):137-49; discussion 149-51. doi: 10.1016/j.eururo.2006.05.021. Epub 2006 Jun 8. PMID: 16793197.

Werntz RP, Smith ZL, Packiam VT, Smith N, Steinberg GD. The Impact of Lymphovascular Invasion on Risk of Upstaging and Lymph Node Metastasis at the Time of Radical Cystectomy. Eur Urol Focus. 2020 Mar 15;6(2):292-7. doi: 10.1016/j.euf.2018.09.019. Epub 2018 Oct 5. PMID: 30297221.

Bolenz C, Hautmann RE. Operative Therapie des Harnblasenkarzinoms: Fortschritte der letzten 50 Jahre [Surgical treatment of bladder cancer: advances made in the past 50 years]. Aktuelle Urol. 2019 Aug;50(4):366-77. German. doi: 10.1055/a-0884-2792. Epub 2019 May 15. PMID: 31091541.

How to Cite
Yakovlev, P. G. (2020). Definite total radical resection in treatment of patients, suffering low-differentiated cancer of the bladder. Klinicheskaia Khirurgiia, 87(11-12), 76-79.
General Problems of Surgery